STOCK TITAN
  1. Home
  2. News
  3. LIAN

LianBio - LIAN STOCK NEWS

Welcome to our dedicated news page for LianBio (Ticker: LIAN), a resource for investors and traders seeking the latest updates and insights on LianBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LianBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LianBio's position in the market.

News
LianBio Announces Voluntarily Delisting from Nasdaq
Rhea-AI Summary
LianBio (LIAN) announces its intent to delist its American Depositary Shares (ADSs) from the Nasdaq Global Market, aiming to focus on other strategic initiatives. The company plans to file a Form 25 with the SEC and Nasdaq for the voluntary delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News
LianBio Announces Completion of Strategic Review
Rhea-AI Summary
LianBio, a biotechnology company, announced the wind down of its operations, including asset sale, delisting from Nasdaq, and issuance of a special cash dividend. The Board's strategic review led to workforce reductions and a special cash dividend of $4.80 per share, totaling around $528 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.81%
Tags
none
-
News
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
Rhea-AI Summary
LianBio (Nasdaq: LIAN) assigns exclusive rights to develop and commercialize NBTXR3 to Janssen, receiving a one-time payment of $25 million and potential sales milestone payment of $5 million. Nanobiotix granted Janssen a worldwide exclusive license for co-development and commercialization of NBTXR3, excepting territories previously licensed to LianBio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News
LianBio Announces Departure of Chief Financial Officer
Rhea-AI Summary
LianBio (Nasdaq: LIAN) announces resignation of CFO and appointment of Interim CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
News
LianBio Announces Departure of Chief Executive Officer
Rhea-AI Summary
LianBio (Nasdaq: LIAN) announces the resignation of CEO Yizhe Wang and the appointment of Adam Stone as Interim CEO. The company is evaluating strategic alternatives for the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
News
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
Rhea-AI Summary
LianBio (NASDAQ: LIAN) rejects unsolicited proposal from Concentra Biosciences, LLC to acquire 100% equity for $4.30 per share in cash, citing undervaluation and not in the best interests of the company or its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
management
News
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Rhea-AI Summary
LianBio (NASDAQ: LIAN) receives an unsolicited proposal from Concentra Biosciences, LLC, offering $4.30 in cash per share and a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs. The proposal is subject to limited confirmatory due diligence and is based on the availability of at least $515 million of cash and cash equivalents at closing, net of any residual liabilities and closing costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
LianBio (Nasdaq: LIAN) reported financial results for Q3 2023, including a strategic review, Phase 3 data from EXPLORER-CN trial of mavacamten, agreement with Bristol Myers Squibb, topline data from TP-03 trial, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
earnings
-
News
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
Rhea-AI Summary
LianBio announces topline results from the Phase 3 LIBRA clinical trial evaluating TP-03 in Chinese patients with Demodex blepharitis. Results show statistically significant mite eradication in patients treated with TP-03 compared to vehicle. TP-03 was well tolerated with a favorable safety profile. LianBio plans to discuss these results with the China National Medical Products Administration and expects to file a New Drug Application in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
clinical trial
News
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
Rhea-AI Summary
LianBio presents data on infigratinib for gastric cancer treatment at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.96%
Tags
clinical trial
Stock LIAN logo
LianBio

Nasdaq:LIAN

LIAN Rankings

#6169 Ranked by Market Cap
#55 Ranked by Stock Gains
N/A Ranked by Dividends

LIAN Stock Data

34.47M
25.38M
5.91%
78.99%
0.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Princeton

About LIAN

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.